Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 5,574 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 5,574 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the sale, the chief executive officer now directly owns 154,828 shares of the company’s stock, valued at approximately $8,450,512.24. The trade was a 3.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Disc Medicine Stock Down 0.2 %

Shares of NASDAQ IRON traded down $0.11 during mid-day trading on Thursday, reaching $54.35. 369,811 shares of the company were exchanged, compared to its average volume of 402,546. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The stock has a market capitalization of $1.62 billion, a PE ratio of -13.66 and a beta of 0.73. The company’s 50 day moving average price is $59.46 and its 200 day moving average price is $55.02.

Analysts Set New Price Targets

A number of brokerages have issued reports on IRON. Jefferies Financial Group started coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price objective for the company. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Scotiabank raised their price target on shares of Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, Wedbush reiterated an “outperform” rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $88.90.

Institutional Trading of Disc Medicine

A number of hedge funds have recently made changes to their positions in IRON. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Disc Medicine by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,717 shares of the company’s stock worth $281,000 after purchasing an additional 2,813 shares during the last quarter. Quest Partners LLC bought a new stake in Disc Medicine in the third quarter worth $131,000. Intech Investment Management LLC bought a new stake in Disc Medicine in the third quarter worth $228,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Disc Medicine by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company’s stock worth $7,890,000 after purchasing an additional 19,401 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.